Corcept Therapeutics (CORT) vs Summit Therapeutics (SMMT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Corcept Therapeutics (CORT) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 32.4% versus a loss of 19.5%. Over five years, CORT leads with a +496.8% price change compared with +248.5% for SMMT. Summit Therapeutics is the larger company by market cap ($13.70 billion vs $12.81 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CORT | SMMT |
|---|---|---|
| Share price | $118.54 | $17.17 |
| Market cap | $12.81B | $13.70B |
| 1-day change | -0.89% | -4.35% |
| YTD return | +243.68% | +2.63% |
| 1-year return | +32.42% | -19.47% |
| 5-year return | +496.81% | +248.54% |
| P/E ratio (TTM) | 263.42 | — |
| Forward P/E | 26.93 | — |
| EPS (TTM) | $0.45 | $-1.11 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $761.41M | — |
| Revenue growth (YoY) | +12.79% | — |
| Net income (latest FY) | $99.65M | $-1.08B |
| Gross margin | 98.30% | — |
| Operating margin | 5.88% | — |
| Net margin | 13.09% | — |
| 52-week high | $126.38 | $29.23 |
| 52-week low | $28.66 | $12.07 |
| Distance from 52-week high | -6.20% | -41.26% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +18.95% | +73.27% |
| Average volume | 1.30M | 5.76M |
| Shares outstanding | 108.10M | 797.75M |
| Employees | 730 | 265 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CORT has outperformed SMMT by 51.9 percentage points over the past year.
About Corcept Therapeutics
CORT stock →Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Health Care · Biotechnology: Pharmaceutical Preparations · 730 employees
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
CORT vs SMMT FAQ
Which is bigger, Corcept Therapeutics or Summit Therapeutics?
Summit Therapeutics (SMMT) is larger, with a market capitalization of $13.70B compared with $12.81B for Corcept Therapeutics (CORT).
Which stock has performed better over the past year, CORT or SMMT?
CORT returned +32.42% over the past 12 months, compared with -19.47% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Corcept Therapeutics and Summit Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.